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| INTRODUC TI ON
Osteosarcoma, a malignant bone tumor mainly affecting children and younger adults, is a very rare tumor that most frequently attacks the long bones and presents with an extremely miserable survival. 1, 2 Usually, the standard treatment for osteosarcoma consists of chemotherapy (including adjuvant chemotherapy and neoadjuvant chemotherapy) and tumor resection. Unfortunately, despite that the survival of patients with localized disease has been predominantly prolonged since the introduction of neoadjuvant chemotherapy, prognosis of patients with metastatic disease remains poor due to the lack of knowledge about the pathogenesis, and also a delay of diagnosis resulting in that most of the patients cannot receive surgery. 3 Therefore, management of osteosarcoma still requires more biomarkers that can aid in diagnosis and surveillance of the disease that are crucial to the extension of survival in these patients.
Circular RNAs (circRNAs), a category of endogenous RNAs united by a structure of closed-loop without a 5ʹ-3ʹ polarity, are a promising class of non-coding RNAs capable of regulating transcriptional or posttranscriptional gene expression via functioning as microRNAs (miRNAs) sponges. [4] [5] [6] [7] Several individual circRNAs have been revealed to play essential roles in osteosarcoma pathogenesis, such as regulating cancer cell cycle, cell proliferation, and chemoresistance, and serving as prognostic biomarker in osteosarcoma patients. [8] [9] [10] CircRNA La-related RNA-binding protein 4 (circ-LARP4) is a novel circRNA derived from the LARP4 gene, a gene encoding Larelated RNA-binding protein that is capable of regulating cancer cell migration and invasion. 11 Furthermore, it is reported that circ-LARP4 could inhibit cancer cell proliferation and invasion in other cancers apart from osteosarcoma. 12 Herein, we speculated that circ-LARP4 might have the potential to be a biomarker in osteosarcoma patients.
Thus, this study aimed to evaluate the association of circ-LARP4 expression with clinical features and prognosis in osteosarcoma patients, and further explore its effect on chemosensitivity in osteosarcoma cells.
| MATERIAL S AND ME THODS

| Patients
Seventy-two osteosarcoma patients with Enneking stage IIA ~ IIB who underwent surgery in our hospital were consecutively enrolled (d) multiple lesions or distant metastasis; (e) history of other malignancies; and (f) pregnant or breastfeeding. The present study was approved by the Ethics Committee of our hospital, and all patients or their guardians signed informed consents before enrollment.
| Collection of samples and baseline data
After completion of the initial diagnosis by X-ray, computed tomography (CT), whole-body magnetic resonance imaging (MRI), or positron emission tomography (PET)-CT, pathological biopsy was performed, including CT-guided core-needle biopsy and open biopsy. Then, tumor tissue samples from biopsy were divided into two parts, one was quickly submitted for pathological assessment and staging, and the other was snap-frozen in the liquid nitrogen and stored at −80°C for further detection. Meanwhile, the corresponding non-tumor tissue of each enrolled patient was also collected from the open biopsy or definitive surgery, which was resected within at least 5 cm of the tumor margin, and the non-tumor tissue was snap-frozen in the liquid nitrogen and stored at −80°C until analysis as well. Patients' baseline clinical data were recorded after the diagnostic workup was completed, which included age, gender, tumor location, World Health Organization (WHO) classification of sarcoma, pathological fracture status, and Enneking stage. And the surgery type was documented after definitive tumor resection.
| Detection of circ-LARP4 in clinical samples
The relative expression of circ-LARP4 in the tumor tissue and nontumor tissue was detected by the quantitative polymerase chain reaction (qPCR). The detailed process was presented in "qPCR" subsection.
| Treatment and assessment
After the diagnosis was established, neoadjuvant chemotherapy with MAP regimen (high-dose methotrexate, cisplatin, and doxorubicin) was administered to all patients for 10 weeks, which consisted of 120 mg/m 2 of cisplatin and 75 mg/m 2 of doxorubicin (weeks 1 and 6) followed by 12 g/m 2 of high-dose methotrexate (weeks 4, 5, 9, and 10) according to the EURAMOS 1 treatment regimen. 13 After the neoadjuvant chemotherapy, patients were re-assessed by the X-ray, PET, or bone scan, and then, definitive surgery (limb salvage or amputation) was performed. The histological response to the neoadjuvant chemotherapy was evaluated on the basis of the tumor cell necrosis rate in the resected specimen, and a good response was defined as tumor cell necrosis rate (TCNR) ≥90%; accordingly, a poor response was defined as TCNR <90%. 14 
| Cell culture
Human osteosarcoma cell lines MG63 and Saos-2 were purchased from American Type Culture Collection (ATCC) (Rockefeller) and then cultured in 90% DMEM (Gibco) supplemented with 10% fetal bovine serum (Gibco) at 37 ℃ under 95% air and 5% CO 2 condition.
| Transfection
Circ-LARP4 overexpression and negative control (NC) overexpression plasmids were constructed by Shanghai QeeJen Bio-tech Company and then were transferred into MG63 and Saos-2 cells, which were divided into Circ-LARP4(+) group and NC(+) group, respectively. Beside, normal MG63 and Saos-2 cells without transfection served as blank control group. Finally, the relative cell viability (%) was calculated by setting corresponding untreated controls (0 μmol/L drug) as 100%, and IC 50 of each drug was calculated.
| Drug sensitivity detection
| Interaction of circ-LARP4 and miR-424
MiR-424 was predicted to be a direct target of circ-LARP4 using Tissue-Specific CircRNA Database (http://gb.whu.edu.cn/TSCD/) and was reported to bind circ-LARP4 to exhibit effect on regulating drug resistance in gastric cancer cells. 12 Besides, miR-424 was proposed to decrease sensitivity to chemotherapy drugs such as cisplatin, 16 docetaxel, 17 doxorubicin, and etoposide. 18 Thus, we hypothesized that circ-LARP4 might regulate drug sensitivity through miR-424 in osteosarcoma. Thus, at 24 hours after transfection, miR-424 expression was detected by qPCR. 
| Rescue experiments
| Luciferase reporter assay
Luciferase reporter assay was carried out using Dual-Luciferase ® Reporter (DLR ™ ) Assay System (Promega). Circ-LARP4 wild-type (WT) plasmid and circ-LARP4 mutant (Mut) plasmid were constructed using pGL4 vector (Promega). Circ-LARP4 WT/Mut plasmid and miR-424(+)/NC(+) plasmid were co-transfected into 293T cells using Lipofectamine 2000 (Thermo), which produced four groups:
WT + NC(+) cells, WT + MiR-424(+) cells, Mut + NC(+) cells, and
Mut + MiR-424(+) cells. At 24 hours after transfection, firefly luciferase luminescence was measured according to the Dual-Luciferase ® Reporter Assay System Protocol.
| qPCR
The relative expressions of circ-LARP4 in the tumor tissue/non-tumor tissue and miR-424 in osteosarcoma cells were detected by the qPCR. Firstly, the total RNA was extracted by RNeasy Protect Mini Kit (Qiagen), and then, the RNase R (Epicenter) was used for the digestion of linear RNA for the detection of circ-LARP4 expression. 19 Secondly, the RNA was reversely transcribed by using the iScript ™ cDNA Synthesis Kit (with random primer) (Bio-Rad), and qPCR was performed by QuantiNova SYBR Green PCR Kit (Qiagen). And the reaction condition was as follows: initial denaturation at 95℃ for 5 minutes, and then 40 cycles of denaturation (94℃, 15 seconds), annealing (61℃, 30 seconds), and extending (72 ℃, 30 seconds), and then an extending at 72℃ for 1 minute. Finally, the relative ex- 
| Statistical analysis
Data processing and analysis were performed using SPSS 24.0 (IBM), and graph plotting was conducted using GraphPad Prism 7.02 (GraphPad Software Inc). Data were described as mean and standard deviation (SD), median and interquartile range (IQR) or count (percentage). Comparison was determined by the t test, Wilcoxon signed-rank test, or chi-square test. Receiver operating characteristic (ROC) curve was used for assessing the value of circ-LARP4 expression for differentiating tumor tissue from non-tumor tissue. Survival curves were estimated using the Kaplan-Meier method, and the difference of survival was determined by the log-rank test. IC 50 was calculated using Probit regression. P value <.05 was considered statistically significant.
| RE SULTS
| Clinical characteristics
The mean age of osteosarcoma patients was 20.6 ± 13.2 years, in which there were 38 (52.8%) patients who had an age below 18 years ( 
| Circ-LARP4 in tumor tissue and nontumor tissue
In osteosarcoma patients, the circ-LARP4 was upregulated in nontumor tissue compared with tumor tissue (P < .001) ( Figure 1A) , and then, the ROC curve analysis disclosed that circ-LARP4 had a good value in distinguishing non-tumor tissue from tumor tissue with an area under curve (AUC) of 0.829 (95% CI: 0.762-0.859) ( Figure 1B ).
| Correlation of circ-LARP4 with clinical features
The association of tumor circ-LARP4 with clinical features was detected, which elucidated that circ-LARP4 was negatively correlated with the Enneking stage (P = .022), while it was not correlated with age (P = 1.000), gender (P = .633), tumor location (P = .750), WHO classification of sarcoma (P = .755), pathological fracture (P = .234), or surgery type (P = .759) in osteosarcoma patients ( Table 2 ).
| Correlation of circ-LARP4 with histological response
After neoadjuvant chemotherapy, the good response rate (TCNR ≥ 90%) was elevated in patients with circ-LARP4 high expression than that in patients with circ-LARP4 low expression (55.6% vs 30.6%, P = .032) ( Figure 2 ).
| Association of circ-LARP4 with survival profiles
With regard to the association of circ-LARP4 with survival profiles in osteosarcoma patients post-treatment, the K-M curve analysis revealed that both DFS (P = .002) ( Figure 3A ) and OS (P = .015) Figure 3B ) were more prolonged in patients with circ-LARP4 high expression in tumor tissue than those in patients with circ-LARP4 low expression.
| Effect of circ-LARP4 on chemosensitivity in MG63 cells
After transfection, the relative cell viability of MG63 cells was de- Figure 4F ). And these results indicated that circ-LARP4 elevated the chemosensitivity of osteosarcoma cells to cisplatin and doxorubicin but not methotrexate, which may also explain the prognostic value of circ-LARP4 in osteosarcoma patients.
| Effect of circ-LARP4 and miR-424 on chemosensitivity in MG63 cells
The Figure 5E ).
Additionally, the luciferase reporter assay displayed the binding site of circ-LARP4 and miR-424 ( Figure S1A,B) . These data suggested that circ-LARP4 might promote chemosensitivity to cisplatin and doxorubicin via sponging miR-424 in osteosarcoma. Figure S2D ). Besides, cell viability of cells treated with 0.02 μmol/L (P < .05), 0.04 μmol/L (P < .05), 0.08 μmol/L (P < .01), and 0.16 μmol/L (P < .05) doxorubicin in Circ-LARP4(+) group was decreased than those in NC(+) group ( Figure S2E) , and the IC 50 value of doxorubicin in the three groups was 0.064, 0.054, and 0.028, respectively ( Figure S2F ). These results indicated that circ-LARP4 elevated the chemosensitivity to cisplatin, methotrexate, and doxorubicin in Sao-S2 cells.
| Effect of circ-LARP4 on chemosensitivity in
SaoS-2 cells
| Effect of circ-LARP4 and miR-424 on chemosensitivity in SaoS-2 cells
After transfections, miR-424 expression was downregulated in Circ- in prostate cancer. 21 Besides, there are also reports illuminating that circRNAs participate in cancer pathogenesis via regulating other related processes. For example, it has been reported that circ-ANKRD12 silencing could induce the changes in molecule and function of the invasive cancer cell phenotypes. 22 Circ-LARP4 is a circRNA derived from the exon 9, exon 10, and intermediate long intron of the LARP4 gene, and this circRNA has been revealed to participate in the regulation of cancer cell functions acting as a miRNA sponge. 12 Generally, as one of the transcripts of the LARP4 gene, circ-LARP4 could directly or indirectly regulate the expression of protein LARP4. As a novel oncogenesis-related circRNA, the studies of its function in cancer are still very insufficient, not to mention that no study has been done to evaluate the role of circ-LARP4 in osteosarcoma. A previous study shows that circ-LAPR4 suppresses cancer cell proliferation and invasion via sponging miR-424-5p and mediating the expression of the larger tumor suppressor kinase 1 (LATS1) in gastric cancer. 12 Another study elucidates that circ-LARP4 activates cancer cell senescence through modulating miR-761/RUNX3/p53/p21 signaling pathway in hepatocellular carcinoma. 23 And the LARP4 gene, the location of circ-LARP4, has also been found to be a tumor suppressor, for example, a recent experiment elucidates that LARP4 gene represses cell motility and migration in ovarian cells. 11 Another experiment illuminates that LARP4 inhibits prostate cancer cell migration and invasion. 24 As for the prognostic value of circ-LARP4, a previous cohort study reports that circ-LARP4 expression is decreased in tumor tissue than that in paired adjacent tissue, and is negatively correlated with Federation of Gynecology and Obstetrics stages and survival in ovarian cancer patients, which is partially in line with our results. 25 In this study, we found that circ-LARP4 was upregulated in non-tumor tissue compared with tumor tissue, and tumor tissue circ-LARP4 high expression was associated with decreased Enneking stage, elevated good response rate, and more satisfactory survival profiles in osteosarcoma patients.
Here are several possible explanations for these results: (a) First, Furthermore, we speculated that circ-LARP4 might have influence on the progression and prognosis of osteosarcoma via affecting the chemosensitivity since that chemotherapy is a predominant part in osteosarcoma treatment. Thus, we investigated the effect of circ-LARP4 on chemosensitivity and its regulatory role of miR-424 in osteosarcoma cells, and found that circ-LARP4 elevated the chemosensitivity to cisplatin and doxorubicin in osteosarcoma cells, and further rescue experiment elucidated that circ-LARP4 might increase chemosensitivity by sponging miR-424. MiR-424, belonging to the miR-424(322)/503 cluster, has been revealed to function as a regulator of development and progression in multiple cancers in prior studies, for instance, miR-424 enhances the progression of esophageal squamous cell carcinoma via promoting cancer cell proliferation through multilayered regulation. 26 And another experiment reveals that miR-424 and miR-19a increase epithelial-to-mesenchymal transition and migration by targeting transforming growth factor type III receptor in tongue squamous cell carcinoma cells. 27 As previously reported in another study, circ-LARP4 represses cell proliferation and invasion of gastric cancer cells via sponging miR-424-5p, which was partially in accordance with our results. 12 These results in our study might provide some novel insights about the role of circ-LARP4 in the progression and prognosis of osteosarcoma.
There were still several limitations in our study: (a) The follow-up duration in our study was relatively short which should be prolonged in the future study; (b) we did not evaluate circ-LARP4 in blood sample, which is easier to obtain from patients and more applicable in clinical practice, and thus, the circulating circ-LARP4
in osteosarcoma patients should be assessed in future studies; and (c) we only included patients in Enneking stage II, and thus, the role of circ-LARP4 in patients in other stages was not evaluated in this study. However, in order to obtain tumor tissue and adjacent tissue, only patients who had received surgery could be included, who were mostly Enneking stage II patients in clinical practice.
In conclusion, circ-LARP4 high expression correlates with decreased Enneking stage, better histological response, and prolonged survival profiles, and it elevates chemosensitivity to cisplatin and doxorubicin via sponging miR-424 in osteosarcoma.
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